中文
2026
Collaboration for More Achievements
- Completed patient enrollment of a Phase III study of mesutoclax in combination with orelabrutinib for treatment-naïve CLL/SLL patients
- Orelabrutinib approved for marketing in Australia
- Soficitinib (ICP-332) Phase III study in AD met primary endpoint
- Soficitinib (ICP-332) Phase II study in vitiligo met primary endpoint
- Fadeucravacitinib (ICP-488) Phase III study in psoriasis met primary endpoint
- ICP-538 became the first VAV1 degrader approved to enter clinical trials in China
2025
Working together for a Brighter Future
- InnoCare celebrated 10th anniversary
- Achieved profitability two years ahead of schedule
- Orelabrutinib approved for first-line treatment of CLL/SLL
- Minjuvi® (tafasitamab) approved for marketing
- Zurletrectinib approved for marketing
- Orelabrutinib approved for the treatment of MZL in Singapore
- Entered into licensing agreement with Zenas for orelabrutinib and other autoimmune pipeline assets
- Entered into licensing partnership with Prolium
2024
Innovate for Brighter Future and Strive for New Heights
- Orelabrutinib received exclusive approval for marginal zone lymphoma (MZL)
- Orelabrutinib annual sales exceeded RMB 1 billion
- Orelabrutinib received U.S. FDA approval to initiate global Phase III trials for PPMS and SPMS
- ICP-488 Phase II study for psoriasis met primary endpoint
2023
Embark on a New Journey
- Entering rapid development of Stage 2.0
- Orelabrutinib for the treatment of r/r marginal zone lymphoma (MZL) approved in China
- Promising data of orelabrutinib for the treatment of multiple sclerosis
- InnoCare and ArriVent achieve clinical development collaboration
2022
Soar to New Heights for a Brighter Future
- InnoCare is listed on the Shanghai Stock Exchange STAR Market (688428.SH)
- Positive Phase IIa results of orelabrutinib for the treatment of systemic lupus erythematosus
- The first prescription of tafasitamab in combination with lenalidomide in Bo‘ao and approved for marketing in Hong Kong
- Orelabrutinib approved for marketing in Singapore
2021
Beyond Dreams, Setting New Milestones
- The first prescription of orelabrutinib to benefit patients with lymphoma in China
- Orelabrutinib granted Breakthrough Therapy designation by the U.S. FDA
- Orelabrutinib included in China’s national reimbursement drug list (NRDL)InnoCare receives the rights to develop and exclusively commercialize tafasitamab in Greater China
2020
Create Exciting Chapters Together
- InnoCare successfully listed on the Hong Kong Stock Exchange (9969.HK)
- Orelabrutinib approved for marketing in China
- Establishment of a dedicated commercial team Completed Phase I of InnoCare Guangzhou Site
2019
Forge Ahead Towards a Promising Future
- Submission of NDA for orelabrutinib in China
2018
Journey to Pursue Dreams
- Orelabrutinib showing efficacy in patients with lymphoma in clinical trials
2017
Dreams Take Off
- Initiated Phase 1 clinical trial of orelabrutinib
2016
Setting Sail
- Established Beijing and Nanjing Research and Development centers
2015
The Beginning
- Dr. Jasmine Cui and Dr. Yigong Shi co-founded InnoCare
